Baltimore biotech, the company that is known for being the sole manufacturer of the stem cell product, has made its plans known, about its intention to go public. The company is slated to sell out nearly $80 million in shares, as per the papers filed with the Securities and Exchange Commission.
Stem cells have been under a lot of scrutiny, and debates have been raging about what this science can really offer. Controversy has always surrounded this area of research and morality issues about stem cells being extracted from human embryos have been clashing with scientific issues. This has led the federal government to reduce major funding of embryonic stem cell research.
